Ongoing Clinical Trial: A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer (AZUR-1)
April 2024
This study aims to investigate dostarlimab therapy in patients with locally advanced mismatch-repair deficient (dMMR) / microsatellite instability high (MSI-H) rectal cancer who have not received any previous treatment. Patients who achieve a complete clinical response (no detectable tumour remains) after treatment with dostarlimab will under non-operative management, which includes close monitoring of any potential cancer recurrence.
The study findings will be used to determine if dostarlimab therapy alone is effective to treatment dMMR/MSI-H locally advanced rectal cancer, allowing patients to be spared additional chemotherapy, surgery, and radiation. For more information about this clinical trial: https://classic.clinicaltrials.gov/ct2/show/NCT05723562
About dostarlimab
Dostarlimab is an immune checkpoint inhibitor (a type of immunotherapy) that is used to treat cancers including colorectal cancer. in a study of 14 patients with early-stage rectal cancer, treatment with dostarlimab prior to surgery led to a remarkable clinical complete response in 100% of the patients. There are currently four different clinical trial sites in Canada for AZUR-1:
Canada, Ontario
GSK Investigational Site
Ottawa, Ontario, Canada, K1H 8L6
Contact: GSKClinicalSupportHD@gsk.com
Principal Investigator: Michael Vickers
Recruiting
Canada, Ontario
GSK Investigational Site
Toronto, Ontario, Canada, M5G 2M9
Contact: GSKClinicalSupportHD@gsk.com
Principal Investigator: Eric Chen
Recruiting
Canada, Quebec
GSK Investigational Site
Montréal, Quebec, Canada, H2X 0A9
Contact: GSKClinicalSupportHD@gsk.com
Principal Investigator: Francine Aubin
Recruiting
Canada, Quebec
GSK Investigational Site
Sherbrooke, Quebec, Canada, J1H 5N4
Contact: GSKClinicalSupportHD@gsk.com
Principal Investigator: Frédéric Lemay
Recruiting
